CTLA4 and neoplasm: Immune checkpoint blockade therapies targeting PD-1, PD-L1 or CTLA-4 showed different levels of activities in clinical application likely due to different roles of the checkpoint molecules in tumour immunosuppression or progression41, 42, 43.